TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07413328: A Phase I, Single-Arm, Open-Label, Dose-Escalation and Expansion Study of HWS116 Injection in Advanced Solid Tumors

Sponsor: Wuhan Humanwell Innovative Drug Research and Development Center Limited Company · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 56 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07413328 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07413328 Rescue Dossier →